RPS6 and non-small cell lung carcinoma: Combined with the clinical findings that only the hyperphosphorylation of rpS6 predicted the unfavorable survival in NSCLC patients, these data provide full evidence that rpS6 abnormal activation as hyperphosphorylation is the key molecule event in the development of NSCLC, and this is probably Akt2 signaling pathway dependent.